Vol. 4 No. 2 (2025)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

THE ROLE OF GUT MICROBIOTA IN METABOLIC DISORDERS: INSIGHTS AND FUTURE THERAPIES

Muhammad Nouman
Nawaz Sharif Medical College Gujrat. Email: noumanmuhammad1657@gmail.com
Sheeza Mehreen
Narowal Medical College Narowal. sheezamehreen17@gmail.com
Daim Qaisar
Nawaz Sharif Medical College Gujrat. daimqaisar1Wagmail.com
Muhammad Wasif
Nawaz Sharif Medical College Gujrat. mw7400661@gmail.com
Muhammad Zubair
Nawaz Sharif Medical College Gujrat. ranazubi6666@gmail.com
Abdullah Shahid
Nawaz Sharif Medical College Gujrat. abddullahking2402@gmail.com

Author Details

Received on 09 June 2025

Accepted on 09 July 2025

Published on 09 July 2025

Corresponding E-mail & Author*:

Abstract

Background: The gut microbiota functions as a vital regulator of host metabolic and immune processes. Disruptions in its composition—termed dysbiosis—are increasingly implicated in metabolic diseases. Objective: This narrative review explores the relationship between gut microbiota and metabolic disorders such as obesity, type 2 diabetes mellitus (T2DM), and non-alcoholic fatty liver disease (NAFLD), highlighting underlying mechanisms and therapeutic implications. Methods: We reviewed foundational and recent literature from PubMed-indexed journals, emphasizing clinical, metagenomic, and interventional studies on gut microbiota in metabolic diseases. Key Findings: Gut microbial shifts, including elevated Firmicutes/Bacteroidetes ratios and SCFA alterations, influence energy harvest, inflammation, and gut permeability. Targeted strategies such as probiotics, prebiotics, synbiotics, and fecal microbiota transplantation (FMT) offer promising but variable outcomes. Conclusion: Gut microbiota modulation represents a frontier in metabolic disease therapy. Precision approaches and standardized methodologies are essential for clinical translation.

INTRODUCTION

GENERAL DEFINITIONS AND IMPORTANCE OF GUT MICROBIOTA

"The gut microbiota represents trillions of organisms located in the gut enteric tract functioning in breakdown of food, absorption of nutrients, and immune protection" [1].

EPIDEMIOLOGICAL DATA ON OBESITY, T2DM, NAFLD

The prevalence of obesity on a global basis and a host of related metabolic diseases such as type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) has increased dramatically, with very serious implications for public health [2,3].

RATIONALE FOR GUT MICROBIOTA'S RELEVANCE TO THESE DISORDERS:

Evidence on the increase in composition of the microbiota of the gut is proposed to be associated with development and progression of the metabolic diseases such as obesity, T2DM, and NAFLD [4–6].



FIGURE 1: ILLUSTRATES HOW DIETARY PATTERNS SHAPE GUT MICROBIOTA COMPOSITION, INFLUENCING INFLAMMATION, METABOLIC RISK, AND INSULIN SENSITIVITY

TRENDS IN RESEARCH

In the last decade, a wave of studies has emerged in the field of gut microbiome during metabolic health, as the application of multi-omics technologies and precision medicine has come to light regarding its ability to be a therapeutic target [7].

COMPOSITION AND FUNCTION OF GUT MICROBIOTA

DOMINANT MICROBES IN A HEALTHY HUMAN GUT

The phyla Firmicutes and Bacteroidetes constitute the major part of a healthy gut microbiota, which receives additional contributions from Actinobacteria and Proteobacteria. As for key genera, they include Bacteroides, Faecalibacterium, and Lactobacillus, and are really important for maintaining metabolic and immune homeostasis [8].

FUNCTIONS:

Digestion: Gut microbes help breakdown of complex carbohydrates and fibres and promote absorption of nutrients [9].

Short-Chain Fatty Acid (SCFA) Production: In the process of fermentation of dietary fibers, gut bacteria (e.g., Faecalibacterium prausnitzii) produces SCFAs such as butyrate, acetate and propionate; which are essential for colon health and energy metabolism [10].

Immune Regulation: Gut microbiota has a regulatory role over immune responses keeping the equilibrium between tolerance and resistance, outnumbering pathogens [11].

FACTORS INFLUENCING COMPOSITION

Diet: Nutritional patterns including consumption of inulin and fructooligosaccharides play major role in affecting the composition of gut microbiota and enhancing beneficial species [12].

Antibiotics: Widespread use of broad-spectrum antibiotic therapies can disorganize microbial balance – dysbiosis [13].

Genetics: Geographic host genetics play a role in the relative abundance of certain microbial taxa [14].

DYSBIOSIS AND METABOLIC DISORDERS

MICROBIOTA CHANGES IN OBESITY, DIABETES, NAFLD

Obesity is characterized by a greater Firmicutes/Bacteroidetes ratio, lower microbial diversity and greater energy harvest [15].

NAFLD patients have changed gut microbiome profiles characterized by increased Proteobacteria and reduced Ruminococcaceae [16].

Comparison of Gut Microbiota Changes in Obesity, T2DM, and NAFLD

Feature	Obesity	T2DM	NAFLD
Firmicutes/Bacteroidetes Ratio	Increased	Variable	Variable
Firmicutes	Increased	Decreased or variable	Increased or unchanged
Bacteroidetes	Decreased	Often decreased	Decreased or variable
Akkermansia muciniphila	Decreased	Decreased	Decreased
Faecalibacterium prausnitzii	Decreased	Decreased	Decreased
Proteobacteria	Increased	Increased	Increased
Enterobacteriaceae	Increased	Increased	Increased
Short Chain Fatty Acids.	Altered	Reduced	Reduced
LPS-producing bacteria	Increased	Increased	Increased
Overall Diversity (Alpha)	Decreased	Decreased	Decreased
Inflammatory Markers	Correlated with dysbiosis	Correlated with dysbiosis	Correlated with dysbiosis

FIGURE 2 : COMPARISON OF GUT MICROBIOTA CHANGES IN OBESITY T2DM AND NAFLD

EVIDENCE LINKING DYSBIOSIS TO METABOLIC DISORDERS

Studies indicate that gut microbiota alterations contribute to insulin resistance, fat accumulation, and systemic inflammation, key features of metabolic disorders [17,18].

MICROBIAL SIGNATURES ASSOCIATED WITH SPECIFIC DISEASES

For instance, Akkermansia muciniphila is often depleted in obesity and T2DM, while an overabundance of Escherichia coli has been linked to NAFLD progression [19,20].

CURRENT INSIGHTS

ROLE OF SHORT-CHAIN FATTY ACIDS (SCFAS)

SCFAs regulate host energy metabolism, stimulate GLP-1 secretion, and improve insulin sensitivity [21].

GUT PERMEABILITY AND ENDOTOXEMIA

Dysbiosis can compromise the gut epithelial barrier, allowing LPS from Gram-negative bacteria into the bloodstream, initiating metabolic endotoxemia [22].

INFLUENCE ON INFLAMMATION AND CYTOKINES

Microbial imbalance can promote pro-inflammatory cytokine production (e.g., TNF-α, IL-6), driving chronic low-grade inflammation [23].

BILE ACID METABOLISM AND ENERGY HARVEST

Gut microbes modify primary bile acids into secondary forms that modulate host metabolism via FXR and TGR5 receptors [24].

GUT-BRAIN AXIS IN APPETITE AND METABOLISM REGULATION

Microbial metabolites affect vagal nerve signaling and central appetite regulation, linking gut microbes to obesity-related behaviors [25].

THERAPEUTIC APPROACHES

PROBIOTICS

Strains such as Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis have shown potential in reducing body weight and improving insulin sensitivity [26,27].

PREBIOTICS:

Prebiotics like inulin and galactooligosaccharides (GOS) enhance the growth of SCFA-producing bacteria, improving glucose homeostasis [28].

SYNBIOTICS:

Combined administration of Bifidobacterium longum and inulin has demonstrated synergistic effects on glycemic control [29].

DIETARY INTERVENTIONS

Mediterranean and plant-based diets, rich in fibers and polyphenols, are linked to increased microbial diversity and metabolic benefits [30].

FECAL MICROBIOTA TRANSPLANTATION (FMT)

FMT from lean donors has improved insulin sensitivity in individuals with metabolic syndrome, though results are variable and safety concerns remain [31,32].

POSTBIOTICS

Postbiotics—non-viable bacterial products or metabolites—such as butyrate and bacterial-derived polysaccharide A, have shown anti-inflammatory and metabolic benefits [33].

CHALLENGES AND RESEARCH GAPS

INTER-INDIVIDUAL VARIATION IN GUT MICROBIOTA

Microbial profiles differ significantly across populations, influencing responses to interventions [34].

DIFFICULTY ESTABLISHING CAUSALITY VERSUS CORRELATION

Most studies are observational; few longitudinal or interventional studies confirm causal roles of microbiota in metabolic disease [35].

LACK OF STANDARDIZATION IN MICROBIOTA STUDIES

Variation in sequencing platforms (e.g., 16S rRNA vs. shotgun metagenomics), data analysis pipelines, and metadata reporting hinder reproducibility [36].

LIMITED LONG-TERM CLINICAL TRIALS

Few trials assess microbiota-targeted therapies beyond 12 weeks; long-term safety and efficacy data are needed [37].

CHALLENGES IN TRANSLATING FINDINGS FROM ANIMAL MODELS TO HUMANS

Species-specific differences limit extrapolation; e.g., mouse models often do not replicate human microbial ecology [38].

NEED FOR PERSONALIZED APPROACHES

Personalized nutrition and microbiome-informed interventions are emerging but require validated biomarkers and tailored algorithms [39].

DISCUSSION:

The intricate relationship between gut microbiota and metabolic disorders is supported by mechanistic studies and clinical correlations. Mechanisms such as SCFA production, endotoxemia, immune modulation, bile acid signaling, and gut-brain communication contribute to obesity, T2DM, and NAFLD.

Therapeutic strategies including probiotics (e.g., L. rhamnosus GG), prebiotics (e.g., inulin), synbiotics, dietary modifications, FMT, and postbiotics have shown varying degrees of efficacy. However, inconsistent results, inter-individual variability, and limited long-term data highlight the need for personalized approaches.

A critical appraisal reveals that much evidence is correlational, often from small or heterogeneous studies. Additionally, translating findings from animal models poses challenges due to species-specific differences.

FUTURE RESEARCH SHOULD

Conduct long-term, randomized, controlled trials with standardized methodologies.

Explore microbiome manipulation in diverse populations.

Integrate multi-omics (metagenomics, metabolomics, transcriptomics)

Leverage AI and machine learning for microbiota-based diagnostics and therapies.

Develop validated biomarkers for microbiome-based personalization.

CONCLUSION:

The gut microbiota plays a pivotal role in the pathogenesis of metabolic disorders, influencing host metabolism through multiple pathways, including SCFA production, bile acid modulation, immune regulation, and gut-brain axis communication. Its modifiable nature offers a promising avenue for innovative therapies aimed at improving metabolic health.

To translate emerging microbiome science into clinical practice, the following recommendations are essential:

1. Integrate microbiome profiling into clinical assessments: Clinicians should consider incorporating gut microbiota analysis, where feasible, as part of the diagnostic and monitoring tools for patients with obesity, type 2 diabetes, or NAFLD to guide targeted interventions.

2. Design personalized interventions based on microbial signatures: Researchers should prioritize developing evidence-based, personalized dietary or probiotic strategies using validated biomarkers of microbial composition and function to enhance treatment efficacy.

3. Conduct long-term, multi-omics-based clinical trials: Future research must include well-powered, longitudinal studies using integrated metagenomics, metabolomics, and transcriptomics to establish causal links and assess the durability of microbiota-targeted therapies.

By addressing these priorities, the field can move toward precision microbiome medicine, ultimately improving outcomes in metabolic disease management.

ACKNOWLEDGMENTS

The authors thank the faculty of Nawaz Sharif Medical College for guidance and support. No funding was received for this study.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. *Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017;474(11):1823–1836.PubMed] [Google Scholar]*

2. *WHO. Obesity and overweight. [Internet]. 2023.*

3. *Younossi ZM, et al. Global epidemiology of NAFLD. Nat Rev Gastroenterol Hepatol.* 2018;15(1):11–20.PubMed] [Google Scholar]

4. *Zmora N, et al. Personalized microbiome-based interventions. Cell Host Microbe. 2019;25(1):32–39.PubMed] [Google Scholar]*

5.Sommer F, Bäckhed F. The gut microbiota—masters of host development and physiology. Nat Rev Microbiol 2013;11:227–238 [DOI] [PubMed] [Google Scholar]

6.Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012;489:242–249 [DOI] [PubMed] [Google Scholar]

7.Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005;102:11070–11075 [DOI] [PMC free article] [PubMed] [Google Scholar]

8.Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005;308:1635–1638 [DOI] [PMC free article] [PubMed] [Google Scholar]

9.Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature 2012;486:222–227 [DOI] [PMC free article] [PubMed] [Google Scholar]

10.Reyes A, Haynes M, Hanson N, et al. Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature 2010;466:334–338 [DOI] [PMC free article] [PubMed] [Google Scholar]

11.Wall R, Ross RP, Ryan CA, et al. Role of gut microbiota in early infant development. Clin Med Pediatr 2009;3:45–54 [DOI] [PMC free article] [PubMed] [Google Scholar]

12.Koenig JE, Spor A, Scalfone N, et al. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci U S A 2011;108(Suppl. 1):4578–4585 [DOI] [PMC free article] [PubMed] [Google Scholar]

13.Claesson MJ, Jeffery IB, Conde S, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012;488:178–184 [DOI] [PubMed] [Google Scholar]

14.Ley RE, Hamady M, Lozupone C, et al. Evolution of mammals and their gut microbes. Science 2008;320:1647–1651 [DOI] [PMC free article] [PubMed] [Google Scholar]

15.Muegge BD, Kuczynski J, Knights D, et al. Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. Science 2011;332:970–974 [DOI] [PMC free article] [PubMed] [Google Scholar]

16.Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013;19:576–585 [DOI] [PMC free article] [PubMed] [Google Scholar]

17.Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011;334:105–108 [DOI] [PMC free article] [PubMed] [Google Scholar]

18.De Filippo C, Cavalieri D, Di Paola M, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A 2010;107:14691–14696 [DOI] [PMC free article] [PubMed] [Google Scholar]

19.Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006;444:1022–1023 [DOI] [PubMed] [Google Scholar]

20.Duncan SH, Lobley GE, Holtrop G, et al. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes (Lond) 2008;32:1720–1724 [DOI] [PubMed] [Google Scholar]